Marijn E. Dekkers - Aug 1, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Aug 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/5/2024, 04:28 PM
Previous filing: Jun 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Disposed to Issuer		-31.8K	-75.26%		10.5K	Aug 1, 2024	Direct	F1
transaction	CERE	Common Stock	Disposed to Issuer		-10.5K	-100%		0	Aug 1, 2024	Direct	F2
transaction	CERE	Common Stock	Disposed to Issuer		-402K	-100%		0	Aug 1, 2024	See Footnote	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Disposed to Issuer		-95.2K	-100%		0	Aug 1, 2024	Common Stock	95.2K		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Marijn E. Dekkers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2	These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3	Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F4	At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.